Influence of cytochrome P450 2C19 gene variations on pharmacokinetic parameters of thalidomide in Japanese patients.

There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

Abstract

Cytochrome P450 (CYP)2C19 polymorphisms may partly explain the variability of thalidomide concentration and adverse drug effects by altering its metabolism. To compare the genetic and clinical factors responsible for the adverse effects and efficacy of thalidomide treatment, we investigated CYP2C19 genetic polymorphisms in Japanese subjects.

Related collections

Author and article information

Journal

Journal ID (iso-abbrev): Biol Pharm Bull

Title: Biological & pharmaceutical bulletin

Publisher: Pharmaceutical Society of Japan

ISSN (Electronic): 1347-5215

ISSN (Print): 0918-6158

Publication date (Electronic): 2012

Volume: 35

Issue: 3

Affiliations

[1 ] Department of Pharmacy, Shinshu University Hospital, Matsumoto, Japan.

Article

Publisher Item ID: JST.JSTAGE/bpb/35.317

DOI: 10.1248/bpb.35.317

PubMed ID: 22382316

SO-VID: 616b0f0c-4e9e-4da7-be4f-0153cc9aec53

History

Data availability:

Comments

Comment on this article

scite_

Smart Citations

Citing PublicationsSupportingMentioningContrasting

View Citations

See how this article has been cited at scite.ai

scite shows how a scientific paper has been cited by providing the context of the citation, a classification describing whether it supports, mentions, or contrasts the cited claim, and a label indicating in which section the citation was made.